Berg Rebecca I M, Nelson Richard W, Feldman Edward C, Kass Philip H, Pollard Rachel, Refsal Kent R
Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, CA 95616, USA.
J Vet Intern Med. 2007 Sep-Oct;21(5):892-8. doi: 10.1892/0891-6640(2007)21[892:sigfci]2.0.co;2.
Serum insulin-like growth factor-I (IGF-I) has been used in place of serum growth hormone quantification for identifying acromegaly in diabetic cats. The utility of IGF-I as a screening test for acromegaly has not been critically evaluated. This retrospective study was performed to evaluate the usefulness of serum IGF-I concentration for identifying acromegaly.
Serum IGF-I is a useful screening test for acromegaly in diabetic cats.
A review was made of the medical records of 74 diabetic cats that had serum IGF-I quantified. The diabetes was classified as well controlled (15 cats), poorly controlled because of problems with the insulin treatment regimen, concurrent disease, or both (40), or poorly controlled with clinical findings consistent with acromegaly (19).
A review of medical records was made.
Serum IGF-I concentration was significantly (P < .0001) increased in acromegalic diabetic cats, compared with well-controlled and poorly controlled diabetic cats. Sensitivity and specificity for serum IGF-I concentration were 84% (95%/ confidence interval [CI] = 60.4-96.6%) and 92% (95% CI = 81.3-97.2%), respectively. There was no significant correlation between serum IGF-I concentration and duration of insulin treatment (r = 0.23, P = .089), insulin dosage (r = 0.14, P = .30), age (r = 0.16, P = .12), and pituitary volume (r = 0.40, P = .11), but a modest correlation was found between serum IGF-I concentration and body weight (r = 0.48, P < .0001).
Results support the use of serum IGF-I concentration as a screening test for acromegaly in diabetic cats that have clinical findings supportive of the disease.
血清胰岛素样生长因子-I(IGF-I)已被用于替代血清生长激素定量检测,以诊断糖尿病猫的肢端肥大症。IGF-I作为肢端肥大症筛查试验的效用尚未得到严格评估。本回顾性研究旨在评估血清IGF-I浓度对诊断肢端肥大症的有用性。
血清IGF-I是糖尿病猫肢端肥大症的有用筛查试验。
回顾了74只进行血清IGF-I定量检测的糖尿病猫的病历。糖尿病被分类为控制良好(15只猫)、因胰岛素治疗方案问题、并发疾病或两者兼而导致控制不佳(40只),或控制不佳且有符合肢端肥大症临床表现(19只)。
回顾病历。
与控制良好和控制不佳的糖尿病猫相比,肢端肥大症糖尿病猫的血清IGF-I浓度显著升高(P <.0001)。血清IGF-I浓度的敏感性和特异性分别为84%(95%置信区间[CI]=60.4 - 96.6%)和92%(95% CI = 81.3 - 97.2%)。血清IGF-I浓度与胰岛素治疗持续时间(r = 0.23,P =.089)、胰岛素剂量(r = 0.14,P =.30)、年龄(r = 0.16,P =.12)和垂体体积(r = 0.40,P =.11)之间无显著相关性,但血清IGF-I浓度与体重之间存在适度相关性(r = 0.48,P <.0001)。
结果支持将血清IGF-I浓度用作对有支持该疾病临床表现的糖尿病猫进行肢端肥大症筛查试验。